To date, RET rearrangement has been identified in approximately 1–2% of NSCLC patients, involving the most common RET fusions: KIF5B-RET (70–90%) and CCDC6-RET (10–25%), followed by NCOA4-RET, TRIM33-RET, ZNF477P-RET, ERCC1-RET, HTR4-RET, and CLIP1-RET (18%) [23–26]. Here, ERCC1 is linked to non-small cell lung carcinoma.